Table 2 Clinical outcomes during study period.
From: The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
All (n = 220) | R group (n = 82) | E group (n = 138) | P value | |
|---|---|---|---|---|
Observational period, days (median) | 152 (56–365) | 153 (58–365) | 149 (51–365) | 0.536 |
Major bleeding | 15 (6.8) | 8 (9.8) | 7 (5.1) | 0.268 |
Respiratory bleeding | 7 (3.2) | 3 (3.7) | 4 (2.8) | 0.714 |
Gastrointestinal bleeding | 7 (3.2) | 4 (4.9) | 3 (2.2) | 0.429 |
Bloody urine | 1 (0.5) | 1 (1.2) | 0 (0) | 0.373 |
Discontinuation events of FXa inhibitors therapy | 50 (22.7) | 24 (29.2) | 26 (18.8) | 0.096 |
Bleeding discontinuation | 31 (14.1) | 18 (22.0) | 13 (9.4) | 0.015 |
Respiratory bleeding | 12 (5.5) | 6 (7.3) | 6 (4.3) | 0.370 |
Gastrointestinal bleeding | 10 (4.5) | 5 (6.1) | 5 (3.6) | 0.506 |
Nose bleeding | 4 (1.8) | 3 (3.7) | 1 (1.4) | 0.147 |
Subcutaneous bleeding | 2 (0.9) | 2 (2.4) | 0 (0) | 0.138 |
Bloody urine | 2 (0.9) | 1 (1.2) | 1 (0.7) | 1.000 |
Genital bleeding | 1 (0.5) | 1 (1.2) | 0 (0) | 0.373 |
Adverse events other than bleeding | 11 (5.0) | 4 (4.9) | 7 (5.1) | 1.000 |
Renal disorder | 4 (1.8) | 1 (1.2) | 3 (2.2) | 1.000 |
Digestive symptoms | 3 (1.4) | 1 (1.2) | 2 (1.4) | 1.000 |
Others | 4 (1.8) | 2 (2.4) | 2 (1.4) | 0.630 |
Thrombosis events | 8 (3.6) | 2 (2.4) | 6 (4.3) | 1.000 |
Cerebral infarction | 4 (1.8) | 0 (0) | 4 (2.8) | 0.299 |
Recurrence or development of VTE | 4 (1.8) | 2 (2.4) | 2 (1.4) | 0.630 |
